Clinical Trial Update: Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on MPV (low-dose bortezomib/melphalan/prednisone) in multiple myeloma; the study is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MPV (low-dose bortezomib/melphalan/prednisone)

Snippet

Sponsor: Basque Health Service | Conditions: Multiple Myeloma | Phase 4 | Status: TERMINATED